|
|
||||||||
INNOVATIVE METHODOLOGY
Novartis Institutes for BioMedical Research, Respiratory Diseases Area, 1Horsham, England and 2Basel, Switzerland
Submitted 4 October 2005 ; accepted in final form 2 December 2005
ABSTRACT
Activation of the adenosine A2A receptor has been postulated as a possible treatment for lung inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD). In this report, we have studied the anti-inflammatory properties of the reference A2A agonist CGS-21680, given intranasally at doses of 10 and 100 µg/kg, in a variety of murine models of asthma and COPD. After an acute ovalbumin challenge of sensitized mice, prophylactic administration of CGS-21680 inhibited the bronchoalveolar lavage fluid inflammatory cell influx but not the airway hyperreactivity to aerosolized methacholine. After repeated ovalbumin challenges, CGS-21680 given therapeutically inhibited the bronchoalveolar lavage fluid inflammatory cell influx but had no effect on the allergen-induced bronchoconstriction, the airway hyperreactivity, or the bronchoalveolar lavage fluid mucin levels. As a comparator, budesonide given intranasally at doses of 0.11 mg/kg fully inhibited all the parameters measured in the latter model. In a lipopolysaccharide-driven model, CGS-21680 had no effect on the bronchoalveolar lavage fluid inflammatory cell influx or TNF-
, keratinocyte chemoattractant, and macrophage inflammatory protein-2 levels, but potently inhibited neutrophil activation, as measured by bronchoalveolar lavage fluid elastase levels. With the use of a cigarette smoke model of lung inflammation, CGS-21680 did not significantly inhibit bronchoalveolar lavage fluid neutrophil infiltration but reversed the cigarette smoke-induced decrease in macrophage number. Together, these results suggest that activation of the A2A receptor would have a beneficial effect by inhibiting inflammatory cell influx and downregulating inflammatory cell activation in asthma and COPD, respectively.
chronic obstructive pulmonary disorder therapies; anti-asthmatic agents; animal models
This article has been cited by other articles:
![]() |
J. A. Marwick, G. Caramori, C. S. Stevenson, P. Casolari, E. Jazrawi, P. J. Barnes, K. Ito, I. M. Adcock, P. A. Kirkham, and A. Papi Inhibition of PI3K{delta} Restores Glucocorticoid Function in Smoking-induced Airway Inflammation in Mice Am. J. Respir. Crit. Care Med., April 1, 2009; 179(7): 542 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Scheibner, S. Boodoo, S. Collins, K. E. Black, Y. Chan-Li, P. Zarek, J. D. Powell, and M. R. Horton The Adenosine A2a Receptor Inhibits Matrix-Induced Inflammation in a Novel Fashion Am. J. Respir. Cell Mol. Biol., March 1, 2009; 40(3): 251 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Hasko and P. Pacher A2A receptors in inflammation and injury: lessons learned from transgenic animals J. Leukoc. Biol., March 1, 2008; 83(3): 447 - 455. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Nadeem, M. Fan, H. R. Ansari, C. Ledent, and S. Jamal Mustafa Enhanced airway reactivity and inflammation in A2A adenosine receptor-deficient allergic mice Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1335 - L1344. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |